Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Works To Stay Focused As Its Heads Spin; Deputies In Spotlight

This article was originally published in The Tan Sheet

Executive Summary

A key challenge for FDA following the resignation of Commissioner Lester Crawford will be overcoming the impression that being without a permanent leader yet again will result in a period of stasis at the agency

You may also be interested in...



Crawford “review”

The HHS Office of the Inspector General is "reviewing the circumstances" surrounding the resignation of FDA Commissioner Lester Crawford in response to requests from members of Congress, IG Daniel Levinson confirmed in a recent letter to Rep. Maurice Hinchey (D-N.Y.) and colleagues. "Depending upon the results of the review, we will determine the next appropriate action," Levinson said. According to OIG staff, the review currently is not a formal investigation. Lawmakers called for the investigation in September (1"The Tan Sheet," Oct. 3, 2005, p. 4)...

Crawford “review”

The HHS Office of the Inspector General is "reviewing the circumstances" surrounding the resignation of FDA Commissioner Lester Crawford in response to requests from members of Congress, IG Daniel Levinson confirmed in a recent letter to Rep. Maurice Hinchey (D-N.Y.) and colleagues. "Depending upon the results of the review, we will determine the next appropriate action," Levinson said. According to OIG staff, the review currently is not a formal investigation. Lawmakers called for the investigation in September (1"The Tan Sheet," Oct. 3, 2005, p. 4)...

Crawford “review”

The HHS Office of the Inspector General is "reviewing the circumstances" surrounding the resignation of FDA Commissioner Lester Crawford in response to requests from members of Congress, IG Daniel Levinson confirmed in a recent letter to Rep. Maurice Hinchey (D-N.Y.) and colleagues. "Depending upon the results of the review, we will determine the next appropriate action," Levinson said. According to OIG staff, the review currently is not a formal investigation. Lawmakers called for the investigation in September (1"The Tan Sheet," Oct. 3, 2005, p. 4)...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS098686

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel